In mouse models of IRI, sustained HIF-1α activation is associated with severe AKI and fibrosis, whereas administration of the HIF-1α inhibitor PX-478 ameliorates the transition from AKI to chronic kidney disease (CKD) (Li et al., 2021a). This evidence concerns the gene HIF1A and chronic kidney disease.